معرفی
Frank Samuel David serves as Professor of the Practice of Biotechnology in the Department of Biology at Tufts University's School of Arts and Sciences, while concurrently leading Pharmagellan LLC as Founder and Managing Director. He contributes to the Harvard-MIT Center for Regulatory Science and bridges academic training with biopharmaceutical industry strategy through consulting, teaching, and research.
Education:
- MD, Columbia University Medical Center (2001)
- PhD, Columbia University Medical Center (2000)
- BS in Molecular Biophysics and Biochemistry, Yale University (1992)
Research Focus: Dr. David specializes in translating complex biomedical R&D into strategic frameworks, with particular expertise in clinical trial interpretation, regulatory pathway optimization, drug pricing models, and R&D risk assessment. His work directly addresses industry pain points through practical handbooks and policy analyses that connect scientific innovation with market realities.
Publication Trends: Recent scholarship examines policy impacts on oncology drug access (2024) and venture capital perspectives on biotech R&D incentives (2022), demonstrating his dual focus on healthcare policy and investment dynamics within the biopharmaceutical ecosystem.
Mentorship & Funding: He guides Tufts biology students toward non-academic careers and offers research opportunities through Pharmagellan. His earlier NIDDK-funded postdoctoral fellowship (1K08DK074429) established his foundation in translational research.
Professional Engagement: As Advisory Board member for the American Cancer Society's BrightEdge Entrepreneurs Program and frequent speaker at Harvard, MIT, and industry conferences, he actively shapes biotech education and innovation strategy.
